In a first model, mutations were acquired probably as a consequence of cytotoxic treatment, where ASXL1 S689* (UPN3), ASXL1 R693* (UPN4), SF3B1 K700E (UPN6) and SETBP1 G870R (UPN13) mutations were only detectable at the time of t-MN diagnosis, and were apparently absent in the BM-MNC harvested at time of primary tumor diagnosis and during follow-up. Here, ASXL1 is linked to neoplasm.